Novartis AG

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey (2023) Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, Fasching P, et al. Journal article Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis (2023) Fitzgerald O, Behrens F, Barton A, Bertheusen H, Boutouyrie-Dumont B, Coates L, Davies O, et al. Journal article, Review article COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma (2023) Berking C, Livingstone E, Debus D, Loquai C, Weichenthal M, Leiter U, Kiecker F, et al. Journal article Laboratory and free-living gait performance in adults with COPD and healthy controls (2023) Buekers J, Megaritis D, Koch S, Alcock L, Ammour N, Becker C, Bertuletti S, et al. Journal article Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial (2023) Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Finzel S, et al. Journal article Patient-reported Outcomes and Burden of Disease in Paediatric Patients with Psoriasis: Real-world Data from EU5 and US (2023) Seyger MM, Paller A, Sticherling M, Bachhuber T, Thomas N, Hetherington J, Lucas J, et al. Journal article Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare (2023) Müller V, Fasching P, Nabieva N, Fehm TN, Thill M, Schmidt M, Kühn T, et al. Journal article, Review article Ecological validity of a deep learning algorithm to detect gait events from real-life walking bouts in mobility-limiting diseases (2023) Romijnders R, Salis F, Hansen C, Küderle A, Paraschiv-Ionescu A, Cereatti A, Alcock L, et al. Journal article Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials (2023) Sticherling M, Nikkels AF, Hamza AM, Kwong P, Szepietowski JC, El Sayed M, Ghislain PD, et al. Journal article Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer (2023) Slamon DJ, Fasching P, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, et al. Journal article